Navigation Links
Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
Date:3/22/2011

BETHESDA, Md., March 22, 2011 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its President, Dr. Robert Lodder, will be presenting at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference to be held at the Grant Hyatt in New York next week.  Dr. Lodder will deliver the Company's corporate presentation on Thursday, March 31, 2011, at 10:45 a.m.

This conference combines BIO-Windhover's partnering event with Pharmaceutical Strategic Outlook for an in-depth analysis on the top issues affecting the industry, creating a dynamic three days of networking and discussion.  The conference offers a personal and interactive setting with in-depth on-stage interviews, panels, one-on-one partnering meetings, and company presentations by carefully selected biotech companies.  Senior level business development and licensing executives from small to large pharmaceutical and biotechnology companies attend BIO-Windhover/PSO to meet their current and potential strategic partners as well as hear from industry stakeholders and key thought leaders who'll share practical advice and strategies on how to structure successful deals.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to development of D-tagatose and recently completed a Phase 3 clinical trial to study the use of D-tagatose as a treatment for Type 2 diabetes.  Biospherics is actively seeking a pharma partner to continue the diabetes development while exploring D-tagatose as a potential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Spherix Transfers Stock Listing to Nasdaq Capital Market
3. Spherix Reports 3rd Quarter Earnings
4. Spherix Announces 2008 Financial Results
5. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
6. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
7. Spherix to Exhibit at the BIO 2009 International Convention
8. Spherix Regains Full NASDAQ Compliance
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Announces Termination of Arla License Agreement
11. Spherix Reports Second Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... year,s edition of the Inc. 5000 features a now-familiar name: BioPoint ( ... the list for the third year in a row. Now in its ... on a set of quantitative metrics. In addition, BioPoint was also named ... Bay State . ... 5000 ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon ... exhibitions for analytical and scientific instruments. This year’s symposium, organized by the Pittcon ... Mass Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, ...
(Date:8/15/2017)... Allentown, PA (PRWEB) , ... August 15, 2017 ... ... and encrypted shopping cart. Now mobile responsive, the new website makes it ... lab or anywhere in between. Users can now find detailed product information, educational ...
(Date:8/11/2017)... Texas (PRWEB) , ... August 11, 2017 , ... A ... rebranding campaign this month that will incorporate important key elements including a new digital ... the community that has supported them, Bill Miller has partnered with the South Texas ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):